LEXEO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.63 USD | +3.61% |
|
+7.57% | +23.92% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 357.6 | 547.9 | - | - |
| Enterprise Value (EV) 1 | 236.1 | 323 | 427.5 | 547.9 |
| P/E ratio | -1.08 x | -6.65 x | -6.8 x | -7.67 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 487 x | 183 x |
| EV / Revenue | - | - | 380 x | 183 x |
| EV / EBITDA | -3,459,997 x | - | - | - |
| EV / FCF | -3.96 x | -4.14 x | -4.89 x | -6.05 x |
| FCF Yield | -25.2% | -24.1% | -20.5% | -16.5% |
| Price to Book | 3.15 x | 3.74 x | 3.05 x | 5.25 x |
| Nbr of stocks (in thousands) | 26,646 | 32,945 | - | - |
| Reference price 2 | 13.42 | 16.63 | 16.63 | 16.63 |
| Announcement Date | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1.125 | 3 |
| EBITDA | - | -68.24 | - | - | - |
| EBIT 1 | - | -68.51 | -92.54 | -104.7 | -136.4 |
| Operating Margin | - | - | - | -9,310.64% | -4,546.47% |
| Earnings before Tax (EBT) 1 | - | -66.39 | -76.49 | -91.53 | -79.66 |
| Net income 1 | -59.28 | -66.39 | -74.59 | -86.04 | -79.27 |
| Net margin | - | - | - | -7,647.69% | -2,642.22% |
| EPS 2 | -36.34 | -12.40 | -2.503 | -2.446 | -2.167 |
| Free Cash Flow 1 | - | -59.61 | -77.93 | -87.5 | -90.6 |
| FCF margin | - | - | - | -7,777.78% | -3,020% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | -20.12 | - | -23.22 | - | - | - | - | - |
| EBIT 1 | -20.27 | -14.97 | -23.29 | -26 | -28 | -30 | -33 | -36 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -20.11 | -14.19 | -21.68 | -22 | -24 | -26 | - | - |
| Net income 1 | -20.11 | -14.19 | -21.68 | -18.18 | -18.18 | -14.67 | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.220 | - | -0.7700 | -0.5991 | -0.5657 | -0.5124 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/23 | 3/11/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 121 | 225 | 120 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -59.6 | -77.9 | -87.5 | -90.6 |
| ROE (net income / shareholders' equity) | - | -58.5% | -61.9% | -46.2% | -47.2% |
| ROA (Net income/ Total Assets) | - | -56.1% | -51% | -39.9% | -40.8% |
| Assets 1 | - | 118.4 | 146.1 | 215.5 | 194.5 |
| Book Value Per Share 2 | - | 4.260 | 4.450 | 5.450 | 3.170 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.12 | 2.43 | 2.73 | 3.15 |
| Capex / Sales | - | - | - | 242.96% | 105% |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.63
USD
Average target price
21.4
USD
Spread / Average Target
+28.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.92% | 548M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- LXEO Stock
- Financials Lexeo Therapeutics, Inc.
